Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MGAM | O43451 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 2/20 | 0.30 |
| ▸ | SI | P14410 | 2/20 | 0.30 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8205181 | 0.76 | ALDH1A1 (0.41) | NPSR1CYP4F2CYP4A11LMNAALDH1A1 | |
| SCHEMBL27894708 | 0.72 | NPSR1 (0.41) | NPSR1CYP4F2CYP4A11LMNA | |
| SCHEMBL1469083 | 0.72 | — | — | |
| SCHEMBL22853899 | 0.71 | OPRM1 (0.32) | OPRM1OPRD1OPRK1 | |
| SCHEMBL8039226 | 0.71 | SMN1; SMN2 (0.35) | NPSR1CYP4F2CYP4A11LMNA | |
| SCHEMBL27009188 | 0.71 | TSHR (0.37) | NPSR1CYP4F2CYP4A11TSHRLMNA | |
| SCHEMBL12987269 | 0.71 | NPSR1 (0.32) | NPSR1CYP4F2CYP4A11 | |
| SCHEMBL15125183 | 0.70 | NPSR1 (0.38) | NPSR1CYP4F2CYP4A11OPRM1OPRD1 | |
| SCHEMBL3382508 | 0.69 | CYP2C19 (0.36) | TSHROPRM1OPRD1OPRK1LMNA | |
| SCHEMBL11139439 | 0.69 | CYP19A1 (0.32) | OPRM1OPRD1OPRK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809264-B2 | Quinoxalinyl macrocyclic hepatitis C virus serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8785377-B2 | Tetrazolyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-7662779-B2 | Triazolyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-20090123423-A1 | HYDROXYAMIC ANALOGS AS HEPATITIS C VIRUS SERINE PROTEASE INHIBITOR | ENANTA PHARMACEUTICALS, INC. | 2009-05-14 | — | — | US | disclosed |
| US-20090098085-A1 | TETRAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090047248-A1 | TRIAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-02-19 | — | — | US | disclosed |
| US-20080317712-A1 | ARYLPIPERIDINYL AND ARYLPYRROLIDINYL TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-12-25 | — | — | US | disclosed |
| US-20080286233-A1 | PIPERIZINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-11-20 | — | — | US | disclosed |
| US-20080274082-A1 | OXIMYL HYDROXYAMIC ANALOGS AS HEPATITIS C VIRUS PROTEASE INHIBITOR | ENANTA PHARMACEUTICALS, INC. | 2008-11-06 | — | — | US | disclosed |
| US-20080038225-A1 | TRIAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080032936-A1 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080274082-A1 | OXIMYL HYDROXYAMIC ANALOGS AS HEPATITIS C VIRUS PROTEASE INHIBITOR | HPN, HCCS, SPINT2 | NPSR1 2289/4885CYP4F2 425/4885CYP4A11 35/4885 |
| US-20080038225-A1 | TRIAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, CTSC | NPSR1 1912/4885CYP4F2 408/4885CYP4A11 69/4885 |
| US-20090047248-A1 | TRIAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | SPINT2, PRSS1, CTSC | NPSR1 2353/4885CYP4F2 384/4885CYP4A11 74/4885 |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | PRSS1, SPINT2, CTSC | NPSR1 2637/4885CYP4F2 410/4885CYP4A11 61/4885 |
| US-20090123423-A1 | HYDROXYAMIC ANALOGS AS HEPATITIS C VIRUS SERINE PROTEASE INHIBITOR | HPN, PRSS1, SERPINB1 | NPSR1 1984/4885CYP4F2 564/4885CYP4A11 142/4885 |
| US-20080317712-A1 | ARYLPIPERIDINYL AND ARYLPYRROLIDINYL TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS | PREP, DNPEP, CTSC | NPSR1 990/4885CYP4F2 505/4885CYP4A11 79/4885 |
| US-20080032936-A1 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | VIP, CTSC, PREP | NPSR1 1436/4885CYP4F2 365/4885CYP4A11 50/4885 |
| US-20090098085-A1 | TETRAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS4, PRSS1, SPINT2 | NPSR1 1600/4885CYP4F2 315/4885CYP4A11 77/4885 |
| US-20080286233-A1 | PIPERIZINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, HPN, PREP | NPSR1 1377/4885CYP4F2 1095/4885CYP4A11 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.